Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
about
High-grade glioma management and response assessment-recent advances and current challengesRecurrent Glioblastoma: Where we standRadiation and concomitant chemotherapy for patients with glioblastoma multiformeCirculating glioma biomarkersMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsModern brain tumor imagingRecent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma PatientsDiffusion and perfusion weighted magnetic resonance imaging for tumor volume definition in radiotherapy of brain tumorsResponse biomarkers: re-envisioning the approach to tailoring drug therapy for cancerPostradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?Diffusion imaging for therapy response assessment of brain tumorPseudoprogression in high-grade glioma.Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-grade gliomas.Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Post-treatment imaging changes in primary brain tumors.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Pros and cons of current brain tumor imagingCharacterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomasA multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice.Recurrent high-grade glioma: a diagnostic and therapeutic challenge.Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.Pseudoprogression: relevance with respect to treatment of high-grade gliomas.Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neuroradiological response criteria for high-grade gliomas.Radiation necrosis following treatment of high grade glioma--a review of the literature and current understanding.Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
P2860
Q26740664-CAD325B7-3BF8-4E96-BFA2-91A88B4AAFAFQ26765042-5B2F9070-5F70-4AEB-A522-7FF3E02B961FQ26827957-610AA83A-34E4-41AC-AA99-689E31CF607FQ26830329-35AD5F22-D797-45B7-93D3-E42A2388CEBAQ26853516-63DB33AA-4E22-4E4A-9473-46E1E2432BDCQ27002344-2A134C74-4B7C-4AD9-A71F-6B2489434A1AQ28066044-E7A36D5E-560A-43E6-BB59-0C2F21FDB0FBQ28067114-8591F210-610B-4F6B-A041-C0E7D3521014Q28074295-9D33F79C-6DD2-46C8-9978-7B2B84078389Q30418915-0E4B84CF-36D8-447D-80D3-BDE1EAA61067Q30437277-A7E1FDB9-4D08-451A-9FEC-6DC5CBBEA2B9Q30578798-C8418932-22BA-434D-A389-7F38B4379266Q30579847-A65FE7BA-49C3-4210-A577-CF5480DC96E3Q30607148-C4EC2BC0-B48E-4475-955E-1458B147F698Q30617625-19F88D18-8D57-402E-98DA-35FCCBC2D1C6Q30636257-FF7206C0-AE6D-40D9-979F-C7348AE43626Q30708866-1080C733-7346-4D89-AA9B-375930E9A34FQ30797166-B091961C-4239-4665-B7C3-C6E0779EA6B4Q30835236-543E56DD-5287-4F93-886B-0E8418457FC8Q30847284-CE69FB07-9413-4254-BDAA-247191B6D74EQ30860126-1332A9C9-0096-4D36-8BAB-7E2954E1140BQ30937034-96EEEF73-8520-4047-8891-67BBC4F8C508Q31038332-F791658F-3E14-4594-8D0F-423290024C0DQ33390586-53A64F9A-5A38-40D5-841F-8A347EEF429CQ33414998-F99F10F2-D530-475A-A383-3CA8A56C0C05Q33447142-49B75EB8-D281-4109-A494-D0293CE1AC5BQ33549622-4FB1A3F9-1F00-4E4D-9521-DB00BB9AED9FQ33818313-9B880C07-0E02-47EF-ADA6-02E54D0F9C50Q33843085-0807D535-9DEE-43D2-AAD1-29DE45120D63Q33862844-A1746792-0044-4701-BB88-6AA348764D1EQ33864058-BCA174A3-BF59-49F6-BB77-56EF8808626DQ33888366-3B4ED1E3-7ED5-4E62-B99C-3C67ED877357Q33894461-7D58F8A5-E3E3-4A54-8953-4678C6289E7FQ33905441-B8640DA9-FE1C-43F3-95EF-8971B3F7D2B3Q33916064-D4EC685F-1185-46DD-96D6-1B94FB8CECEFQ33935125-D18B78C8-ADFE-435F-9792-8648E5CD0C01Q34087196-4EB89E30-CCFF-40F9-92EA-BF40FDAFAA5EQ34089398-F2C5C6B1-9077-45B4-B02C-9F6868D81BC8Q34132767-3502248B-5419-4622-84B3-DC0E6582C4F6Q34186787-F8CA48A9-AFEA-406D-8ECE-BBBC00EA0116
P2860
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@ast
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@en
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@nl
type
label
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@ast
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@en
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@nl
prefLabel
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@ast
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@en
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@nl
P2093
P2860
P356
P1433
P1476
Incidence of early pseudo-prog ...... irradiation with temozolomide.
@en
P2093
Annemarie T Swaak-Kragten
Corine A van Es
Dieta Brandsma
Hein G de Bruin
Jacoline E Bromberg
Martin J van den Bent
Peter A E Sillevis Smitt
Walter Taal
P2860
P304
P356
10.1002/CNCR.23562
P407
P577
2008-07-01T00:00:00Z